Related references
Note: Only part of the references are listed.Nusinersen treatment of spinal muscular atrophy: current knowledge and existing gaps
Teresa Gidaro et al.
DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY (2019)
Putting our best foot forward: Clinical, treatment-based and ethical considerations of nusinersen therapy in Canada for spinal muscular atrophy
Sonya Vukovic et al.
JOURNAL OF PAEDIATRICS AND CHILD HEALTH (2019)
Neurofilament as a potential biomarker for spinal muscular atrophy
Basil T. Darras et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2019)
Pre-Nusinersen Hospitalization Costs of Children With Spinal Muscular Atrophy
Michael Lee et al.
PEDIATRIC NEUROLOGY (2019)
Single-center experience with intrathecal administration of Nusinersen in children with spinal muscular atrophy type 1
Astrid Pechmann et al.
EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY (2018)
Time Is Motor Neuron: Therapeutic Window and Its Correlation with Pathogenetic Mechanisms in Spinal Muscular Atrophy
Alessandra Govoni et al.
MOLECULAR NEUROBIOLOGY (2018)
Nusinersen in type 1 SMA infants, children and young adults: Preliminary results on motor function
Marika Pane et al.
NEUROMUSCULAR DISORDERS (2018)
Clinical phenotypes and trajectories of disease progression in type 1 spinal muscular atrophy
Roberto De Sanctis et al.
NEUROMUSCULAR DISORDERS (2018)
Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy
E. Mercuri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Nusinersen in patients older than 7 months with spinal muscular atrophy type 1 A cohort study
Karolina Aragon-Gawinska et al.
NEUROLOGY (2018)
Expanded access program with Nusinersen in SMA type I in Italy: Strengths and pitfalls of a successful experience
Sonia Messina et al.
NEUROMUSCULAR DISORDERS (2017)
Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
R. S. Finkel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Natural history of infantile-onset spinal muscular atrophy
Stephen J. Kolb et al.
ANNALS OF NEUROLOGY (2017)
Developmental milestones in type I spinal muscular atrophy
Roberto De Sanctis et al.
NEUROMUSCULAR DISORDERS (2016)
209th ENMC International Workshop: Outcome Measures and Clinical Trial Readiness in Spinal Muscular Atrophy 7-9 November 2014, Heemskerk, The Netherlands
Richard Finkel et al.
NEUROMUSCULAR DISORDERS (2015)
Observational study of spinal muscular atrophy type I and implications for clinical trials
Richard S. Finkel et al.
NEUROLOGY (2014)
SMA-EUROPE workshop report: opportunities and challenges in developing clinical trials for spinal muscular atrophy in Europe
Nathalie Kayadjanian et al.
ORPHANET JOURNAL OF RARE DISEASES (2013)
Validation of the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND)
Allan M. Glanzman et al.
PEDIATRIC PHYSICAL THERAPY (2011)
The Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND): Test development and reliability
A. M. Glanzman et al.
NEUROMUSCULAR DISORDERS (2010)
Natural history of denervation in SMA:: Relation to age, SMN2 copy number, and function
KJ Swoboda et al.
ANNALS OF NEUROLOGY (2005)